In the last trading session, 1.02 million Fulcrum Therapeutics Inc (NASDAQ:FULC) shares changed hands as the company’s beta touched 2.39. With the company’s per share price at $6.88 changed hands at -$0.22 or -3.10% during last session, the market valuation stood at $371.38M. FULC’s last price was a discount, traded about -47.24% off its 52-week high of $10.13. The share price had its 52-week low at $2.32, which suggests the last value was 66.28% up since then. When we look at Fulcrum Therapeutics Inc’s average trading volume, we note the 10-day average is 0.68 million shares, with the 3-month average coming to 573.15K.
Analysts gave the Fulcrum Therapeutics Inc (FULC) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.00. If we narrow down to specifics, the data shows that 0 out of 13 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 4 recommended FULC as a Hold, 9 felt it is a Buy and 0 rated the stock as Underweight.
Fulcrum Therapeutics Inc (NASDAQ:FULC) trade information
Instantly FULC was in red as seen at the end of in last trading. With action -4.04%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 11.51%, with the 5-day performance at -4.04% in the red. However, in the 30-day time frame, Fulcrum Therapeutics Inc (NASDAQ:FULC) is -2.69% down. Looking at the short shares, we see there were 5.82 million shares sold at short interest cover period of 10.67 days.
The consensus price target for the stock as assigned by Wall Street analysts is 10.5, meaning bulls need an upside of 34.48% from its current market value. According to analyst projections, FULC’s forecast low is 9 with 12 as the target high. To hit the forecast high, the stock’s price needs a -74.42% plunge from its current level, while the stock would need to soar -30.81% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 54.59%. The 2025 estimates are for Fulcrum Therapeutics Inc earnings to decrease by -630.36%.
FULC Dividends
Fulcrum Therapeutics Inc is expected to release its next quarterly earnings report on 2025-May-01.
Fulcrum Therapeutics Inc (NASDAQ:FULC)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.82% of Fulcrum Therapeutics Inc shares while 96.20% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 97.98%. There are 96.20% institutions holding the Fulcrum Therapeutics Inc stock share, with RA CAPITAL MANAGEMENT, L.P. the top institutional holder. As of 2024-06-30, the company held 18.6636% of the shares, roughly 11.61 million FULC shares worth $71.98 million.
RTW INVESTMENTS, LP holds the second largest percentage of outstanding shares, with 9.3979% or 5.85 million shares worth $36.24 million as of 2024-06-30.
